Lundbeck Halts P-II Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia

 Lundbeck Halts P-II Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia

Lundbeck Halts P-II Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia

Shots:

  • The company discontinues P-II proof POC study of Lu AF11167 in patients with schizophrenia, who are experiencing persistent negative symptoms (NCT03793712). The P-II study evaluated two doses of Lu AF11167 vs PBO as monothx. in patients with schizophrenia and persistent prominent negative symptoms
  • The discontinuation is based on the results of a futility interim analysis, which concluded that trial fails to achieve 1EPs i.e. change from baseline to 12wk on BNSS. The recommendation to halt the trial is not based on safety concerns
  • Lu AF11167 is a potent PDE10Ai inhibitor, modulating dopamine D1 and D2 receptor-mediated intraneuronal signaling without binding to these receptors. The company plans to randomize 240 patients from EU countries

Click here ­to­ read full press release/ article | Ref: Lundbeck | Image: Lundbeck

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post